HC Wainwright Raises Earnings Estimates for Ikena Oncology

Ikena Oncology, Inc. (NASDAQ:IKNA) – Research analysts at HC Wainwright lifted their FY2024 EPS estimates for shares of Ikena Oncology in a research note issued on Monday, November 11th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($0.95) per share for the year, up from their prior estimate of ($1.07). HC Wainwright currently has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for Ikena Oncology’s current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Ikena Oncology’s Q4 2024 earnings at ($0.20) EPS, Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.81) EPS, FY2026 earnings at ($0.95) EPS, FY2027 earnings at ($0.93) EPS and FY2028 earnings at ($0.70) EPS.

Separately, Wedbush reissued a “neutral” rating and set a $2.00 price objective on shares of Ikena Oncology in a report on Thursday, November 7th.

Ikena Oncology Stock Performance

Shares of NASDAQ:IKNA opened at $1.69 on Thursday. The firm has a market cap of $81.56 million, a price-to-earnings ratio of -1.37 and a beta of 0.48. The firm has a fifty day moving average price of $1.71 and a 200 day moving average price of $1.65. Ikena Oncology has a fifty-two week low of $1.22 and a fifty-two week high of $2.32.

Ikena Oncology (NASDAQ:IKNA) last released its earnings results on Thursday, November 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.08.

Hedge Funds Weigh In On Ikena Oncology

Several institutional investors have recently bought and sold shares of the business. NEA Management Company LLC lifted its holdings in shares of Ikena Oncology by 5.3% in the 3rd quarter. NEA Management Company LLC now owns 600,063 shares of the company’s stock valued at $1,038,000 after acquiring an additional 30,013 shares during the last quarter. BBR Partners LLC lifted its stake in shares of Ikena Oncology by 550.0% in the 3rd quarter. BBR Partners LLC now owns 130,000 shares of the company’s stock valued at $225,000 after purchasing an additional 110,000 shares during the last quarter. FMR LLC lifted its stake in shares of Ikena Oncology by 94.1% in the 3rd quarter. FMR LLC now owns 38,374 shares of the company’s stock valued at $66,000 after purchasing an additional 18,607 shares during the last quarter. BML Capital Management LLC boosted its holdings in shares of Ikena Oncology by 23.6% in the 3rd quarter. BML Capital Management LLC now owns 723,288 shares of the company’s stock worth $1,251,000 after purchasing an additional 138,174 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Ikena Oncology during the 2nd quarter valued at approximately $75,000. Institutional investors own 75.00% of the company’s stock.

Ikena Oncology Company Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.